Nasopharyngeal Carcinoma Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | BeiGene, Coherus, Harbour BioMed, Innovent Biologics, Junshi Biosciences, Novartis

Nasopharyngeal Carcinoma Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | BeiGene, Coherus, Harbour BioMed, Innovent Biologics, Junshi Biosciences, Novartis
Delveinsight Business Research LLP
As per DelveInsight’s assessment, the Nasopharyngeal Carcinoma therapeutics market is anticipated to grow in the coming years owing to the rise in the number of cases of Nasopharyngeal Carcinoma, the increase in the R&D activities, the development & launch of targeted products and immunotherapies with better efficacy.

DelveInsight’s “Nasopharyngeal Carcinoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Nasopharyngeal Carcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Nasopharyngeal Carcinoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Nasopharyngeal Carcinoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Nasopharyngeal Carcinoma: An Overview

Nasopharyngeal Cancer is a type of head and neck cancer that affects the part of the throat connecting the back of the nose to the back of the mouth (nasopharynx). It should not be confused with other types of cancer affecting the throat, such as laryngeal and oesophageal cancer.

Most nasopharyngeal cancers are nasopharyngeal carcinoma (NPC). There are three types of NPC. They all start from epithelial cells that line the nasopharynx, but the cells of each type look different under a microscope. Three types include non-keratinizing undifferentiated carcinoma, non-keratinizing differentiated carcinoma, and keratinizing squamous cell carcinoma.

The exact cause of nasopharyngeal cancer is unknown, but a number of factors can increase your risk of developing the condition, which includes being of South Chinese or North African descent, having a diet very high in salt-cured meats and fish, being exposed to the Epstein-Barr virus (EBV).

This type of cancer can be treated with a multidisciplinary approach. The main treatment option is radiation therapy, however, it is often given in combination with chemotherapy. This approach may be called concomitant chemoradiotherapy.

Surgery for NPC is occasionally used, mainly to remove lymph nodes after chemoradiotherapy or to treat NPC that has come back after initial treatment. Palliative therapy is also used to control the symptoms related to cancer and its treatment. Chemotherapy is also the option of choice when distant metastasis is involved. NPC with distant poly-metastasis is offered palliative chemotherapy. The agents of choice are cisplatin and 5-fluorouracil. With recent advances, several chemotherapeutic agents are available for the continuation of therapy.

Nasopharyngeal Carcinoma Market Key Facts

  • According to the National Health Services (NHS), nasopharyngeal cancer affects men about 3 times more than women.

  • According to the American Cancer Society, about half of the people with nasopharyngeal cancer in the United States are younger than 55 years old, and the average age at diagnosis is about 50.

  • As per the data by Globocan, approximately 133,300+ people were affected by nasopharynx cancer across the globe in 2020; the United States accounted for 1,890+ incident cases of nasopharynx carcinoma.

  • Some of the key players in the therapeutic market include Tessa Therapeutics, BeiGene, Innovent Biologics (Suzhou), Novartis Pharmaceuticals, Jiangsu HengRui, Harbour BioMed, and others.

  • The expected launch of emerging therapies such as TT10, Tislelizumab, and others for treating Nasopharyngeal Cancers shall fuel the market size growth in the upcoming years.

  • The dynamics of the Nasopharyngeal Cancer market are anticipated to change in the coming year. Some of the key players are actively working in the therapeutic market to improve the Nasopharyngeal Carcinoma treatment scenario. The emerging therapeutics treatment options in Nasopharyngeal Cancer Landscape are more focused on developing targeted products and immunotherapies for better efficacy.

Nasopharyngeal Carcinoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Nasopharyngeal Carcinoma pipeline therapies. It also thoroughly assesses the Nasopharyngeal Carcinoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Nasopharyngeal Carcinoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Nasopharyngeal Carcinoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Nasopharyngeal Carcinoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Nasopharyngeal Carcinoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Nasopharyngeal Carcinoma Epidemiology, Segmented as –

  • Total Incidence of Nasopharyngeal Cancer in the 7MM (2019-2032)

  • Treated Pool of Nasopharyngeal Cancer (total NPC patient pool including recurrent cases) in the 7MM (2019-2032)

  • Age-specific Incidence of Nasopharyngeal Cancer in the 7MM (2019-2032)

  • Stage-wise Incidence of Nasopharyngeal Cancer in the 7MM (2019-2032)

  • Gender-specific Incidence of Nasopharyngeal Cancer in the 7MM (2019-2032)

  • Recurrent/Metastatic Incidence of Nasopharyngeal Cancer in the 7MM (2019-2032)

Nasopharyngeal Carcinoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Nasopharyngeal Carcinoma market or expected to be launched during the study period. The analysis covers the Nasopharyngeal Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Nasopharyngeal Carcinoma drugs based on their sale and market share.

The report also covers the Nasopharyngeal Carcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Nasopharyngeal Carcinoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Nasopharyngeal Carcinoma Market Will Evolve and Grow by 2032 @

Nasopharyngeal Carcinoma Therapeutics Analysis

The treatment options and recommendations for nasopharyngeal cancer depend on several factors, including the type and stage of cancer, possible side effects, and the patient’s preferences and overall health. The approach is mainly multidisciplinary several professional works together and make decisions, known as shared decision-making. It is particularly important for nasopharyngeal cancer because there are different treatment options.

Chemotherapy is used in different situations to treat nasopharyngeal cancer like it can be often used together with radiation therapy as the first treatment for more advanced stages of nasopharyngeal cancer because some chemodrugs make cancer cells more sensitive to radiation. It may also be given after radiation as an adjuvant treatment. Common chemo drugs that are used in the treatment of nasopharyngeal cancer include carboplatin (PARAPLATIN), Doxorubicin (ADRIAMYCIN), epirubicin (ELLENCE), paclitaxel (TAXOL), docetaxel (TAXOTERE), gemcitabine (GEMZAR), bleomycin, methotrexate.

In targeted therapies, ERBITUX (cetuximab) is mainly used in the treatment of nasopharyngeal cancer. Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Nasopharyngeal cancer cells sometimes have more than normal amounts of EGFR, which can help them grow faster. By blocking EGFR, cetuximab may slow or stop this growth.

In immunotherapies, mainly KEYTRUDA and OPDIVO are used, which are PD-1 inhibitors. It can be used after chemotherapy and these are mainly used in metastatic cancer. A number of companies are evaluating immunotherapies in combination with PD1/PDL1 inhibitors for the treatment of head and neck cancers, including nasopharyngeal cancer. The use of immunotherapy for recurrent nasopharyngeal carcinoma patients is an active area of clinical research.

Nasopharyngeal Carcinoma Companies Actively Working in the Therapeutics Market Include

  • Atara Biotherapeutics

  • BeiGene

  • Coherus

  • Harbour BioMed

  • Innovent Biologics (Suzhou)

  • Jiangsu HengRui

  • Junshi Biosciences

  • Novartis Pharmaceuticals

  • Tessa Therapeutics

And Many Others

Emerging and Marketed Nasopharyngeal Carcinoma Therapies Covered in the Report Include:

  • Tislelizumab: BieGene

  • Tabelecleucel plus Keytruda: Atara Biotherapeutics

  • PDR001: Novartis

  • Toripalimab: Junshi Biosciences/ Coherus

  • HBM9167: Harbour BioMed

  • TT10: Tessa Therapeutics

  • Sintilimab: Innovent Biologics

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Nasopharyngeal Carcinoma Competitive Intelligence Analysis

4. Nasopharyngeal Carcinoma Market Overview at a Glance

5. Nasopharyngeal Carcinoma Disease Background and Overview

6. Nasopharyngeal Carcinoma Patient Journey

7. Nasopharyngeal Carcinoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Nasopharyngeal Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Nasopharyngeal Carcinoma Unmet Needs

10. Key Endpoints of Nasopharyngeal Carcinoma Treatment

11. Nasopharyngeal Carcinoma Marketed Therapies

12. Nasopharyngeal Carcinoma Emerging Drugs and Latest Therapeutic Advances

13. Nasopharyngeal Carcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Nasopharyngeal Carcinoma Market Outlook (In US, EU5, and Japan)

16. Nasopharyngeal Carcinoma Companies Active in the Market

17. Nasopharyngeal Carcinoma Access and Reimbursement Overview

18. KOL Views on the Nasopharyngeal Carcinoma Market

19. Nasopharyngeal Carcinoma Market Drivers

20. Nasopharyngeal Carcinoma Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Endometrial Cancer Market

“Endometrial Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Endometrial Cancer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Endometrial Cancer market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States